Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROY: Trastuzumab deruxtecan vs investigator’s choice chemotherapy in recurrent ovarian cancer after PARP inhibitor
KCT0011110Phase 2Not yet recruiting
- Sponsor
- Yonsei University Health System
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in ovarian cancer, recurrent ovarian cancer (ROC), sponsored by Yonsei University Health System. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
ovarian cancerrecurrent ovarian cancer (ROC)
Beyond the preview
Go deeper on KCT0011110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011110.